DK1607090T3 - Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome) - Google Patents

Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)

Info

Publication number
DK1607090T3
DK1607090T3 DK05016750.1T DK05016750T DK1607090T3 DK 1607090 T3 DK1607090 T3 DK 1607090T3 DK 05016750 T DK05016750 T DK 05016750T DK 1607090 T3 DK1607090 T3 DK 1607090T3
Authority
DK
Denmark
Prior art keywords
azimadoline
treatment
bowel syndrome
irritable bowel
irritable
Prior art date
Application number
DK05016750.1T
Other languages
English (en)
Inventor
Karl-August Ackermann
Inge Stein
Rudolf Gottschlich
Bernd Helfert
Andreas Bathe
Jens Budak
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7865063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1607090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1607090T3 publication Critical patent/DK1607090T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02—Reduction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DK05016750.1T 1998-04-20 1999-04-16 Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome) DK1607090T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817393 1998-04-20
DE19827633A DE19827633A1 (de) 1998-04-20 1998-06-20 Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
EP99923421A EP1073634B1 (de) 1998-04-20 1999-04-16 Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Publications (1)

Publication Number Publication Date
DK1607090T3 true DK1607090T3 (da) 2012-01-30

Family

ID=7865063

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05016750.1T DK1607090T3 (da) 1998-04-20 1999-04-16 Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)
DK99923421T DK1073634T3 (da) 1998-04-20 1999-04-16 Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99923421T DK1073634T3 (da) 1998-04-20 1999-04-16 Fremgangsmåde til fremstilling af enantiomerrent N-methyl-N[(1S)-1-phenyl-2-2((3S)-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Country Status (28)

Country Link
US (1) US6344566B1 (da)
EP (2) EP1073634B1 (da)
JP (1) JP4688292B2 (da)
KR (1) KR100649175B1 (da)
CN (2) CN1846696A (da)
AR (2) AR019080A1 (da)
AT (2) ATE303361T1 (da)
AU (2) AU761721B2 (da)
BR (1) BR9909731A (da)
CA (1) CA2329210C (da)
CY (1) CY1112314T1 (da)
CZ (1) CZ301121B6 (da)
DE (2) DE19827633A1 (da)
DK (2) DK1607090T3 (da)
ES (2) ES2375384T3 (da)
HK (1) HK1039111A1 (da)
HU (1) HUP0101600A3 (da)
MY (1) MY120471A (da)
NO (1) NO317984B1 (da)
PL (1) PL206969B1 (da)
PT (1) PT1607090E (da)
RU (1) RU2298549C2 (da)
SI (2) SI1607090T1 (da)
SK (2) SK286442B6 (da)
TW (1) TWI249524B (da)
UA (1) UA73472C2 (da)
WO (1) WO1999054298A1 (da)
ZA (1) ZA200006689B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
US20070160559A1 (en) * 2006-01-12 2007-07-12 Roszell James A Skin disinfectant composition and methods for using
JP5416085B2 (ja) 2007-03-30 2014-02-12 ティオガ ファーマシューティカルズ インコーポレイテッド 下痢型および交替型過敏性腸症候群の処置のためのカッパ−オピエートアゴニスト
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN112574068A (zh) * 2020-11-17 2021-03-30 万华化学（宁波）有限公司 一种低色号高稳定性碳化二亚胺改性异氰酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
AU3384697A (en) * 1996-07-24 1998-02-10 Warner-Lambert Company Diphenyl-cyclopropenes as selective k-agonists
DE19647538A1 (de) * 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Also Published As

Publication number Publication date
DK1073634T3 (da) 2006-01-09
HUP0101600A3 (en) 2002-12-28
CY1112314T1 (el) 2015-12-09
PL206969B1 (pl) 2010-10-29
ES2375384T3 (es) 2012-02-29
RU2298549C2 (ru) 2007-05-10
AU761721B2 (en) 2003-06-05
TWI249524B (en) 2006-02-21
EP1073634A1 (de) 2001-02-07
PL343556A1 (en) 2001-08-27
AR019080A1 (es) 2001-12-26
CZ20003860A3 (cs) 2001-01-17
ATE303361T1 (de) 2005-09-15
EP1607090B1 (de) 2011-10-12
CZ301121B6 (cs) 2009-11-11
DE59912502D1 (de) 2005-10-06
KR100649175B1 (ko) 2006-11-24
CN1310884C (zh) 2007-04-18
NO317984B1 (no) 2005-01-17
AU2003248428B2 (en) 2005-10-20
ZA200006689B (en) 2002-02-18
AR066455A2 (es) 2009-08-19
DE19827633A1 (de) 1999-10-21
WO1999054298A1 (de) 1999-10-28
SK288016B6 (sk) 2012-11-05
SI1073634T1 (sl) 2006-02-28
NO20005259L (no) 2000-10-19
UA73472C2 (en) 2005-08-15
ES2251194T3 (es) 2006-04-16
HK1039111A1 (en) 2002-04-12
CA2329210A1 (en) 1999-10-28
PT1607090E (pt) 2012-01-10
SK15572000A3 (sk) 2001-05-10
BR9909731A (pt) 2000-12-19
CA2329210C (en) 2008-03-04
CN1297435A (zh) 2001-05-30
EP1607090A1 (de) 2005-12-21
JP2002512223A (ja) 2002-04-23
NO20005259D0 (no) 2000-10-19
KR20010042750A (ko) 2001-05-25
AU4031199A (en) 1999-11-08
CN1846696A (zh) 2006-10-18
EP1073634B1 (de) 2005-08-31
AU2003248428A1 (en) 2003-11-06
JP4688292B2 (ja) 2011-05-25
US6344566B1 (en) 2002-02-05
SK286442B6 (sk) 2008-10-07
MY120471A (en) 2005-10-31
ATE527999T1 (de) 2011-10-15
HUP0101600A2 (hu) 2001-09-28
SI1607090T1 (sl) 2012-01-31

Similar Documents

Publication Publication Date Title
DK1123284T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1008577T4 (da) Fremgangsmåde til fremstilling af methanol
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK2412368T3 (da) Sammensætning til behandling af ar
DK1077940T3 (da) 4-Phenylpiperidiner til behandling af pruritiske dermatoser
DK1173431T4 (da) Fremgangsmåde til fremstilling af citalopram
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
DK0923978T3 (da) Fremgangsmåde til behandling af röggas
DK1206436T3 (da) Retinoider til behandling af emfysem
DK0930091T3 (da) Fremgangsmåde til behandling af röggasser
DK199800837A (da) Anlæg til behandling af emner
BR9907304B1 (pt) refratÁrio de alumina-magnÉsia-grafita.
DK0996642T3 (da) Fremgangsmåde til fremstilling af heparin
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK1607090T3 (da) Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)
DK0970939T3 (da) Fremgangsmåde til fremstilling af methanol
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner
DK0862939T3 (da) Fremgangsmåde til behandling af röggas
DK1298124T3 (da) Fremgangsmåde til fremstilling af citalopram
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
DK0981950T3 (da) Fremgangsm,åde til formering af phyllocactus